Mutual Destruction of Deep Lung Tumor Tissues by Nanodrug‐Conjugated Stealth Mesenchymal Stem Cells

Lung cancer is a highly malignant tumor, and targeted delivery of anti‐cancer drugs to deep lung tumor tissue remains a challenge in drug design. Here, it is demonstrated that bone marrow mesenchymal stem cells armed with nanodrugs are highly targeted and mutually destructive with malignant lung can...

Full description

Saved in:
Bibliographic Details
Published in:Advanced science 2018-05, Vol.5 (5), p.1700860-n/a
Main Authors: Kim, Sang‐Woo, Lee, Yeon Kyung, Hong, Jeong Hee, Park, Jun‐Young, Choi, Young‐Ae, Lee, Dong Un, Choi, Jungil, Sym, Sun Jin, Kim, Sang‐Hyun, Khang, Dongwoo
Format: Article
Language:English
Subjects:
Bone marrow
Brain cancer
Cancer therapies
Chemokines
Clinical trials
Drugs
Genetic engineering
Histology
homing abilities
in vivo safety
Laboratory animals
Lung cancer
lung tumors
mesenchymal stem cells
mutual destruction
nanodrug membrane conjugation
Stem cells
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is a highly malignant tumor, and targeted delivery of anti‐cancer drugs to deep lung tumor tissue remains a challenge in drug design. Here, it is demonstrated that bone marrow mesenchymal stem cells armed with nanodrugs are highly targeted and mutually destructive with malignant lung cancer cells and successfully eradicate lung tumors tissues. Using this approach, the current clinical dose of anti‐cancer drugs for the treatment of malignant lung tumors can be decreased by more than 100‐fold without triggering immunotoxicity. Lung cancer targetable fluorescent mesenchymal stem cells are armed with anti‐cancer nanodrugs in blood vessels and are shown to be selectively homing to lung tumor sites and mutually destructive with lung cancer cells. Using this method, the current clinical dose of anti‐cancer drugs for the treatment of malignant lung tumors can be decreased by more than 100‐fold without triggering immunotoxicity.
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.201700860